Stockscreener 앱 받기
5.39
3.06%
0.16
전일 마감가:
$5.23
열려 있는:
$5.4
하루 거래량:
25,467
Relative Volume:
0.76
시가총액:
$33.66M
수익:
$4.71M
순이익/손실:
$-90.32M
주가수익비율:
-0.6193
EPS:
-8.7032
순현금흐름:
$-85.19M
1주 성능:
+1.51%
1개월 성능:
+8.02%
6개월 성능:
-27.36%
1년 성능:
-48.07%
1일 변동 폭
$5.186
$5.409
1주일 범위
$5.186
$5.64
52주 변동 폭
$3.98
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
명칭
Aligos Therapeutics Inc
전화
(800) 466-6059
주소
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
5.39 | 33.66M | 4.71M | -90.32M | -85.19M | -8.7032 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-28 | 개시 | Lake Street | Buy |
| 2026-05-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-03-19 | 재개 | Jefferies | Buy |
| 2025-08-18 | 재개 | H.C. Wainwright | Buy |
| 2024-08-19 | 개시 | H.C. Wainwright | Buy |
| 2023-01-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-01-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-09 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 재개 | Piper Sandler | Overweight |
| 2020-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 개시 | JP Morgan | Overweight |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Aligos Therapeutics Inc 주식(ALGS)의 최신 뉴스
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket - Benzinga
TScan Therapeutics (Nasdaq:TCRX)Stock Analysis - simplywall.st
Aligos Therapeutics at Cantor Fitzgerald conference: hbv pipeline in focus By Investing.com - Investing.com India
Aligos Therapeutics at Cantor Fitzgerald conference: hbv pipeline in focus By Investing.com - Investing.com UK
Liquidity Mapping Around (ALGS) Price Events - Stock Traders Daily
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference - Investing News Network
Why is Aligos Therapeutics stock rallying 7% today? - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference - Yahoo Finance
Why is Aligos Therapeutics stock rallying 7% today? By Investing.com - Investing.com India
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates - Yahoo Finance
Stock Market News - Investing.com South Africa
Why is Aligos Therapeutics stock rallying 7% today? By Investing.com - Investing.com UK
Aligos Therapeutics (ALGS) Stock Forum and Discussion - Moomoo
Aligos Hepatitis B Trial Completion: What Phase 1 Liver Data Mean for ALGS Investors - TipRanks
Aligos Therapeutics Company Profile & Introduction - Moomoo
Aligos Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Why (ALGS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Industry Analysts Just Upgraded Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts By 68% - Moomoo
Aligos Therapeutics (ALGS) Slips 1.55% to $6.67 as Biotech Stock Holds Above Key SupportSector Leader Stocks - vinanet.vn
Aligos Therapeutics Company Profile & Introduction - Moomoo
Aligos Therapeutics (ALGS) Slips 1.55% to $6.67 as Biotech Stock Holds Above Key SupportSafe Entry Stocks - dars.gov.et
Aligos Therapeutics, Inc. (ALGS) Stock Price, News, Quote & History - Yahoo Finance
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - Investing News Network
Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China - TradingView
Aligos begins phase 1 trial of hepatitis B treatment in China - Investing.com South Africa
Aligos begins phase 1 trial of hepatitis B treatment in China - Investing.com
Aligos begins phase 1 trial of hepatitis B treatment in China - Investing.com Nigeria
Aligos begins phase 1 trial of hepatitis B treatment in China - Investing.com Canada
Aligos begins phase 1 trial of hepatitis B treatment in China - Investing.com Australia
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - The Manila Times
Aligos Begins Testing a Chronic Hepatitis B Candidate in China - Stock Titan
Industry Analysts Just Made A Stunning Upgrade To Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts - simplywall.st
Industry Analysts Just Made A Stunning Upgrade To Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts - simplywall.st
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - Yahoo Finance
H.C. Wainwright reiterates Aligos stock rating on HBV progress By Investing.com - Investing.com UK
H.C. Wainwright reiterates Aligos stock rating on HBV progress By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Aligos stock rating on HBV progress - Investing.com
H.C. Wainwright reiterates Aligos stock rating on HBV progress By Investing.com - Investing.com UK
H.C. Wainwright reiterates Aligos stock rating on HBV progress - Investing.com
Lake Street Keeps Their Buy Rating on Aligos Therapeutics (ALGS) - The Globe and Mail
Aligos Therapeutics Inc (NASDAQ:ALGS) - intelligentinvestor.com.au
ALGS Q2 2026 Earnings: Narrowed Loss Beats Estimates by 87% as Stock Advances 1.45Healthcare Earnings Report - Vinanet
Cantor Fitzgerald Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Aligos earnings beat by $1.01, revenue topped estimates - Investing.com Canada
Form 8K Aligos Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Form 8K Aligos Therapeutics Inc For: 6 August - Investing.com India
Form 8K Aligos Therapeutics Inc For: 6 August By Investing.com - Investing.com Canada
Aligos Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aligos Therapeutics Reports $1.5 Million Q2 Net Loss and Pipeline Progress | ALGS Stock News - Quiver Quantitative
Aligos Therapeutics Inc (ALGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.35%
자본화:
|
볼륨(24시간):